Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ( " Viking " ) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 27, 2024 Category: Pharmaceuticals Source Type: clinical trials
Enrollment Completed of the IgA Nephropathy Cohort in the Phase II Clinical Trial of the ETA Receptor Antagonist SC0062
WUXI, China, Feb. 25, 2024. BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Phase I Study of Human Interferon Alfa 1b Inhalation Solution in Healthy Participants
Conditions: Healthy Participants Interventions: Drug: Human interferon alfa 1b inhalation solution; Drug: Human interferon alfa 1b inhalation solution placebo; Drug: Human interferon alfa 1b inhalation solution; Drug: Human interferon alfa 1b inhalation solution placebo Sponsors: Kexing Biopharm Co., Ltd.; Guoxin Pharmaceutical Technology (Beijing) Co., Ltd.; The Third Hospital of Changsha; Beijing SSYP Data Technology Development Co.,Ltd.; United-Power Pharma Tech （Shanghai）Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial for Gepotidacin in Uncomplicated Urogenital Gonorrhoea (GC)
London, UK 26 February 2024 GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations
Berlin, Germany, February 26, 2024– Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Antibody Reduces Allergic Reactions to Multiple Foods in NIH Clinical Trial
February 25, 2024 -- A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 24, 2024 Category: Pharmaceuticals Source Type: clinical trials
Phase I Clinical Trial of Zolmitriptan Transdermal Microporation System Initiated for the Treatment of Acute Migraine
SAN DIEGO, Feb. 23, 2024. PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study of Zolmitriptan PassPort utilizing its proprietary transdermal microporation system, PassPort platform technology. The... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 23, 2024 Category: Pharmaceuticals Source Type: clinical trials
Multi-centre, Open-label, First-in-man Study With Mucopad HA
Conditions: Oral Mucositis Interventions: Device: Mucopad HA Sponsors: Contipro Pharma a.s. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Mix of Demineralized Freeze-Dried Bone Allograft and Deproteinized Bovine Bone Mineral: a Possible Solution for Alveolar Ridge Preservation?
Conditions: Alveolar Ridge Preservation; Dental Extraction; Bone Graft Interventions: Procedure: Alveolar ridge preservation Sponsors: Nova Southeastern University; Geistlich Pharma AG; ZimVie Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
BOSTON, Feb. 22, 2024 . Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic Stroke
Conditions: Ischemic Stroke, Acute; Diabetes Mellitus, Type 2; Blood Brain Barrier Interventions: Drug: Cerebrolysin; Procedure: Brain-MRI with contrast after 10-14 days of cerebrolysin Sponsors: Hospital Universitario Dr. Jose E. Gonzalez; Ever Neuro Pharma GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects
Conditions: Periodontitis; Furcation Defects Interventions: Procedure: Access flap& surgical debridement; Procedure: Application of bone substitute material (BioOss Collagen) Sponsors: G öteborg University; Johann Wolfgang Goethe University Hospital; Charite University, Berlin, Germany; King ' s College London; Queen Mary University of London; Geistlich Pharma AG; Vastra Gotaland Region Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection
Malvern, PA, Parsippany, NJ, and Florence, Italy– February 20, 2024– Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 20, 2024 Category: Pharmaceuticals Source Type: clinical trials
